← Back to Screener
Allogene Therapeutics, Inc. Common Stock (ALLO)
Price$2.42
Favorite Metrics
Price vs S&P 500 (26W)85.56%
Price vs S&P 500 (4W)5.97%
Market Capitalization$582.63M
All Metrics
Book Value / Share (Quarterly)$1.28
P/TBV (Annual)3.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-91.70%
Cash Flow / Share (Quarterly)$-0.65
Price vs S&P 500 (YTD)70.31%
Net Profit Margin (TTM)-269835.03%
EPS (TTM)$-0.87
10-Day Avg Trading Volume26.86M
EPS Excl Extra (TTM)$-0.87
EPS (Annual)$-0.87
ROI (Annual)-65.25%
Net Profit Margin (5Y Avg)-3191.05%
Cash / Share (Quarterly)$1.09
ROA (Last FY)-45.90%
EBITD / Share (TTM)$-0.89
ROE (5Y Avg)-53.63%
Operating Margin (TTM)-274487.82%
Cash Flow / Share (Annual)$-0.65
P/B Ratio1.99x
P/B Ratio (Quarterly)1.05x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2695.13x
ROA (TTM)-41.63%
EPS Incl Extra (Annual)$-0.87
Current Ratio (Annual)7.93x
Quick Ratio (Quarterly)7.74x
3-Month Avg Trading Volume7.60M
52-Week Price Return70.71%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.68
P/S Ratio (Annual)26483.15x
Asset Turnover (Annual)0.00x
52-Week High$4.46
Operating Margin (5Y Avg)-3267.44%
EPS Excl Extra (Annual)$-0.87
CapEx CAGR (5Y)-64.23%
26-Week Price Return94.31%
Quick Ratio (Annual)7.74x
13-Week Price Return40.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.93x
Enterprise Value$530.941
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-30.18%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1168850.00%
Cash / Share (Annual)$1.09
3-Month Return Std Dev121.83%
Net Income / Employee (TTM)$-1
ROE (Last FY)-65.25%
EPS Basic Excl Extra (Annual)$-0.87
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.87
Receivables Turnover (Annual)0.01x
ROI (TTM)-57.07%
P/S Ratio (TTM)2957.51x
Pretax Margin (5Y Avg)-3192.20%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.68
Price vs S&P 500 (52W)35.62%
Year-to-Date Return74.45%
5-Day Price Return-21.90%
EPS Normalized (Annual)$-0.87
ROA (5Y Avg)-41.84%
Net Profit Margin (Annual)-1170863.64%
Month-to-Date Return-2.05%
Cash Flow / Share (TTM)$-2.12
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-1241813.64%
ROI (5Y Avg)-53.63%
EPS Basic Excl Extra (TTM)$-0.87
P/TBV (Quarterly)3.28x
P/B Ratio (Annual)1.05x
Pretax Margin (TTM)-269835.03%
Book Value / Share (Annual)$1.28
Price vs S&P 500 (13W)37.72%
Beta0.54x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.07%
52-Week Low$0.86
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.14
4.14
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALLOAllogene Therapeutics, Inc. Common Stock | 2957.51x | — | — | — | $2.42 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf allogeneic CAR T-cell therapies for cancer and autoimmune diseases. Its genetically engineered, donor-derived T-cell products offer broader patient eligibility and manufacturing scalability compared to autologous therapies. The pipeline targets lymphoma, leukemia, solid tumors, and autoimmune disorders, with revenue generated from collaborations and licensing agreements.